Gonzalo Luis Alonso Salinas

Prof. Dr. Gonzalo Luis Alonso Salinas

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2017 in Molecules
Verified
Journal Article
Open access
PDF file
MBMaria-José Bagur-Fuster
Maria-José Bagur-Fuster
Gonzalo Luis Alonso SalinasGonzalo Luis Alonso Salinas
Gonzalo Luis Alonso Salinas
AJAntonia M. Jiménez-Monreal
Antonia M. Jiménez-Monreal
SCSoukaina Chaouqi
Soukaina Chaouqi
Sílvia LlorensSílvia Llorens
Sílvia Llorens
GAGonzalo L. Alonso
Gonzalo L. Alonso
The spice saffron is made from the dried stigmas of the plant Crocus sativus L. The main use of saffron is in cooking, due to its ability to impart colour, flavour and aroma to foods and beverages. However, from time immemorial it has also been considered a medicinal plant because it possesses therapeutic properties, as illustrated in paintings found on the island of Santorini, dated 1627 BC. It is included in Catalogues of Medicinal Plants and in the European Pharmacopoeias, being part of a great number of compounded formulas from the 16th to the 20th centuries. The medicinal and pharmaceutical uses of this plant largely disappeared with the advent of synthetic chemistry-produced drugs. However, in recent years there has been growing interest in demonstrating saffron’s already known bioactivity, which is attributed to the main components—crocetin and its glycosidic esters, called crocins, and safranal—and to the synergy between the compounds present in the spice. The objective of this work was to provide an updated and critical review of the research on the therapeutic properties of saffron, including activity on the nervous and cardiovascular systems, in the liver, its antidepressant, anxiolytic and antineoplastic properties, as well as its potential use as a functional food or nutraceutical.

1 November 2016 in International Journal of Cardiology
Verified
Journal Article
Closed access
Gonzalo Luis Alonso SalinasGonzalo Luis Alonso Salinas
Gonzalo Luis Alonso Salinas
MSMarcelo Sanmartín
Marcelo Sanmartín
MIMarina Pascual Izco
Marina Pascual Izco
ÁCÁlvaro Marco del Castillo
Álvaro Marco del Castillo
LRLuis Miguel Rincón
Luis Miguel Rincón
JGJosé Luis Zamorano Gómez
José Luis Zamorano Gómez

1 July 2015 in European Heart Journal: Acute Cardiovascular Care
Verified
Journal Article
Closed access
Gonzalo Luis Alonso SalinasGonzalo Luis Alonso Salinas
Gonzalo Luis Alonso Salinas
MSMarcelo Sanmartín
Marcelo Sanmartín
MIMarina Pascual Izco
Marina Pascual Izco
RARoberto Martín Asenjo
Roberto Martín Asenjo
ARAlejandro Recio-Mayoral
Alejandro Recio-Mayoral
JGJosé Luis Zamorano Gómez
José Luis Zamorano Gómez
Frailty is a biological condition that reflects a state of decreased physiological reserve and vulnerability to stressors. The role of frailty in acute coronary syndrome patients has not been fully explored. Our study aims to assess the prevalence of frailty and its impact on in-hospital adverse outcomes of patients aged ⩾75 years admitted for acute coronary syndrome. This prospective, observational study included patients aged ⩾75 years admitted due to type 1 myocardial infarction in four tertiary hospitals. Frailty was assessed by the SHARE-FI index. The primary endpoint was the combination of in-hospital death or non-fatal myocardial (re)infarction. Secondary endpoints included the assessment of individual rates of (re)infarction, mortality, stroke, major bleeding and the combination of in-hospital death, (re)infarction and mortality. A total of 202 patients were analysed. Frail patients (n=71, 35.1%) were older, more often women, had higher rates of comorbidities, and a higher risk profile according to GRACE, TIMI and CRUSADE scores at admission. The primary endpoint was significantly more frequent among frail patients (9.9% vs. 1.5%; P=0.006), as well as the combination of death, myocardial infarction and stroke (11.3% vs. 1.5%; P=0.002), driven mainly by a higher mortality rate (8.5% vs 0.8%; P=0.004). On multivariate analysis, frailty phenotype was an independent predictor of major adverse cardiac events (odds ratio 7.13; 95% confidence interval 1.43–35.42). Over one third of elderly patients with high-risk acute coronary syndrome are frail. Frailty phenotype is an important and independent prognostic marker in these patients.

16 July 2017 in Clinical Cardiology
Verified
Journal Article
Open access
PDF file
Gonzalo Luis Alonso SalinasGonzalo Luis Alonso Salinas
Gonzalo Luis Alonso Salinas
MSMarcelo Sanmartín
Marcelo Sanmartín
MIMarina Pascual Izco
Marina Pascual Izco
LRLuis Miguel Rincón
Luis Miguel Rincón
PPPablo Pastor Pueyo
Pablo Pastor Pueyo
JZJosé Luis Zamorano
José Luis Zamorano
Background: Acute coronary syndrome (ACS) patients are increasingly older. Conventional prognostic scales include chronological age but do not consider vulnerability. In elderly patients, a frail phenotype represents a better reflection of biological age.Hypothesis: This study aims to determine the prevalence of frailty and its influence on patients age ≥75 years with ACS.Methods: Patients age ≥75 years admitted due to type 1 myocardial infarction were included in 2 tertiary hospitals, and clinical data were collected prospectively. Frailty was defined at admission using the previously validated Survey of Health Ageing and Retirement in Europe Frailty Index (SHARE‐FI) tool. The primary endpoint was the combination of death or nonfatal myocardial reinfarction during a follow‐up of 6 months. Major bleeding (hemoglobin decrease ≥3 g/dL or transfusion needed) and readmission rates were also explored.Results: A total of 234 consecutive patients were included. Frail patients (40.2%) had a higher‐risk profile, based on higher age and comorbidities. On multivariate analysis, frailty was an independent predictor of the combination of death or nonfatal myocardial reinfarction (adjusted hazard ratio [aHR]: 2.54, 95% confidence interval [CI]: 1.12‐5.79), an independent predictor of the combination of death, nonfatal myocardial reinfarction, or major bleeding (aHR: 2.14, 95% CI: 1.13‐4.04), and an independent predictor of readmission (aHR: 1.80, 95% CI: 1.00‐3.22).Conclusions: Frailty phenotype at admission is common among elderly patients with ACS and is an independent predictor for severe adverse events. It should be considered in future risk‐stratification models.

1 September 2019 in Revista Española de Cardiología (English Edition)
Verified
Journal Article
Closed access
TLTeresa López-Fernández
Teresa López-Fernández
AMAna Martín-García
Ana Martín-García
IRInmaculada Roldán Rabadán
Inmaculada Roldán Rabadán
CMCristina Mitroi
Cristina Mitroi
PRPilar Mazón Ramos
Pilar Mazón Ramos
JZJosé Luis Zamorano
José Luis Zamorano

1 June 2018 in Gerontology
Verified
Journal Article
Closed access
PDF file
Gonzalo Luis Alonso SalinasGonzalo Luis Alonso Salinas
Gonzalo Luis Alonso Salinas
MSMarcelo Sanmartín
Marcelo Sanmartín
MIMarina Pascual Izco
Marina Pascual Izco
LRLuis Miguel Rincón
Luis Miguel Rincón
AMAlba Martin-Acuna
Alba Martin-Acuna
JZJosé Luis Zamorano
José Luis Zamorano
Background: Myocardial infarction (MI) patients are increasingly older, and common risk scores include chronological age, but do not consider chronic comorbidity or biological age. Frailty status reflects these variables and may be independently correlated with prognosis in this setting. Objective: This study investigated the impact of frailty on the prognosis of elderly patients admitted due to MI. Methods: This prospective and observational study included patients ≥75 years admitted to three tertiary hospitals in Spain due to MI. Frailty assessment was performed at admission using the Survey of Health, Ageing and Retirement in Europe Frailty Index (SHARE-FI) tool. The primary endpoint was the composite of death or non-fatal reinfarction during a follow-up of 1 year. Overall mortality, reinfarction, the composite of death, reinfarction and stroke, major bleeding, and readmission rates were also explored. Results: A total of 285 patients were enrolled. Frail patients (109, 38.2%) were older, with a higher score in the Charlson Comorbidity Index and with a higher risk score addressed in the GRACE and CRUSADE indexes. On multivariate analysis including GRACE, CRUSADE, maximum creatinine level, culprit lesion revascularization, complete revascularization, and dual antiplatelet therapy at discharge, frailty was an independent predictor of the composite of death and reinfarction (2.81, 95% CI 1.16–6.78) and overall mortality (3.07, 95% CI 1.35–6.98). Conclusion: Frailty is an independent prognostic marker of the composite of mortality and reinfarction and of overall mortality in patients aged ≥75 years admitted due to MI.